Avenue Therapeutics Appoints Dr. James N. Woody as CMO
Ticker: ATXI · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1644963
Sentiment: neutral
Topics: management-change, personnel
TL;DR
Avenue Therapeutics just hired a new CMO, Dr. James N. Woody, to help push their drug through approvals.
AI Summary
Avenue Therapeutics, Inc. announced on June 24, 2024, the appointment of Dr. James N. Woody as Chief Medical Officer and a member of the Board of Directors. Dr. Woody brings extensive experience in drug development and regulatory affairs, having previously held leadership roles at companies like Amgen and Pfizer. This appointment is part of Avenue Therapeutics' ongoing efforts to advance its pipeline, particularly its investigational therapy for IV tramadol.
Why It Matters
The appointment of an experienced Chief Medical Officer like Dr. Woody is crucial for Avenue Therapeutics as it navigates the complex drug development and regulatory approval process for its lead investigational therapy.
Risk Assessment
Risk Level: medium — The company is in the clinical development stage, and the success of its investigational therapy is not guaranteed, posing inherent risks.
Key Players & Entities
- Avenue Therapeutics, Inc. (company) — Registrant
- Dr. James N. Woody (person) — Appointed Chief Medical Officer and Board Member
- Amgen (company) — Previous employer of Dr. Woody
- Pfizer (company) — Previous employer of Dr. Woody
- IV tramadol (drug) — Investigational therapy
FAQ
When was Dr. James N. Woody appointed as Chief Medical Officer?
Dr. James N. Woody was appointed as Chief Medical Officer on June 24, 2024.
What is Avenue Therapeutics' lead investigational therapy?
Avenue Therapeutics' lead investigational therapy is for IV tramadol.
What other roles has Dr. James N. Woody held?
Dr. Woody has held leadership roles at companies such as Amgen and Pfizer.
What is the state of incorporation for Avenue Therapeutics, Inc.?
Avenue Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Avenue Therapeutics, Inc.?
The principal executive office address is 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154.
Filing Stats: 983 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2024-06-26 16:52:41
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (the " Common Stock "), and 2
Filing Documents
- atxi20240625_8k.htm (8-K) — 40KB
- ex_692668.htm (EX-10.1) — 6KB
- 0001437749-24-021302.txt ( ) — 178KB
- atxi-20240624.xsd (EX-101.SCH) — 3KB
- atxi-20240624_def.xml (EX-101.DEF) — 11KB
- atxi-20240624_lab.xml (EX-101.LAB) — 15KB
- atxi-20240624_pre.xml (EX-101.PRE) — 11KB
- atxi20240625_8k_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On June 24, 2024, the Company held its 2024 Annual Meeting at 9:30 a.m. Eastern Time by means of an online virtual meeting platform. Stockholders representing 482,053 shares of the Company's common stock, par value $0.0001 per share (the " Common Stock "), and 250,000 shares of the Company's Class A Preferred Stock were represented in person or by proxy, representing a majority of the outstanding voting power of the Company, and thereby constituting a quorum. At the 2024 Annual Meeting, the following three proposals were approved: (i) the election of six directors to hold office until the 2025 annual meeting of stockholders; (ii) the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024; and (iii) the 2015 Plan Amendment. The three proposals are described in detail in Avenue's 2024 Proxy Statement. As of the April 30, 2024 record date for the determination of the stockholders entitled to notice of, and to vote at, the 2024 Annual Meeting, 595,524 shares of Common Stock were outstanding and eligible to vote with an aggregate of 595,524 votes and 250,000 shares of the Company's Class A Preferred Stock were outstanding and eligible to vote with an aggregate of 650,000 votes, as determined in accordance with Article IV, Section 2.1.2 of the Company's Third Amended and Restated Certificate of Incorporation, as amended. Proposal 1 The votes with respect to the election of six directors to hold office until the 2025 annual meeting of stockholders were as follows: Director Votes For Votes Withheld Broker Non-Votes Jay Kranzler, M.D., Ph.D. 704,444 20,092 157,517 Faith Charles 704,702 19,834 157,517 Neil Herskowitz 704,291 20,245 157,517 Alexandra MacLean, M.D. 705,060 19,476 157,517 Curtis Oltmans 704,494 20,042 157,517 Lindsay A. Rosenwald, M.D. 704,169 20,367 157,517 Proposal
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibit is furnished herewith: Exhibit Number Description 10.1 Amendment to the Avenue Therapeutics, Inc. 2015 Incentive Plan. 104 Cover Page Interactive Data File (embedded within Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVENUE THERAPEUTICS, INC. (Registrant) Date: June 26, 2024 By: /s/ David Jin David Jin Interim Principal Financial Officer and Chief Operating Officer